Search

BioMarin Pharmaceutical Inc

Closed

SectorHealthcare

67.34 -1.51

Overview

Share price change

24h

Current

Min

66.91

Max

68.52

Key metrics

By Trading Economics

Income

-61M

45M

Sales

224M

990M

P/E

Sector Avg

172.2

57.002

EPS

0.9

Profit margin

4.523

Employees

3,221

EBITDA

50M

222M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34.93% upside

Dividends

By Acuity

Next Earnings

26 paź 2026

Market Stats

By TradingEconomics

Market Cap

1.7B

13B

Previous open

68.85

Previous close

67.34

News Sentiment

By Acuity

2%

98%

1 / 340 Ranking in Healthcare

BioMarin Pharmaceutical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

13 sie 2026, 22:36 UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

12 sie 2026, 23:01 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

11 sie 2026, 19:56 UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

10 sie 2026, 23:26 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

7 sie 2026, 23:16 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

6 sie 2026, 23:02 UTC

News

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

5 sie 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

4 sie 2026, 19:46 UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

3 sie 2026, 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

31 lip 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

30 lip 2026, 19:08 UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

29 lip 2026, 18:14 UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

28 lip 2026, 18:02 UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

27 lip 2026, 19:01 UTC

News

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

24 lip 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 lip 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 lip 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 lip 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

16 lip 2026, 19:06 UTC

Macro Event
News

Citi analyst raises price target on Biomarin Pharmaceutical to $76.00, maintaining a Buy rating. Shares are higher today amid positive sentiment and notable volatility.

15 lip 2026, 23:21 UTC

Biomarin Pharmaceutical shares are higher in after-market trading, nearing the upper end of their one-month range amid broader market concerns over geopolitical tensions.

14 lip 2026, 19:31 UTC

Event

Biomarin Pharmaceutical shares are lower today, tracking declines in the Biotechnology sub-sector, continuing a downward trend since Monday's close.

13 lip 2026, 19:46 UTC

News
Event

BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO has been accepted by the FDA. Shares are lower today amid broader market sentiment.

10 lip 2026, 23:46 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, retracing from earlier highs. No specific news was identified to explain the movement.

9 lip 2026, 19:16 UTC

Biomarin Pharmaceutical Inc. shares are trading roughly flat with no specific news identified. The stock remains above its 20-day moving average.

8 lip 2026, 23:46 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

7 lip 2026, 23:32 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market trading, reflecting routine activity despite broader market volatility following Samsung Electronics' disappointing news.

6 lip 2026, 20:06 UTC

Biomarin Pharmaceutical shares are lower today, continuing a decline since Thursday. No specific news was identified to explain the trading activity.

2 lip 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 lip 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

Peer Comparison

Price change

BioMarin Pharmaceutical Inc Forecast

Price Target

By TipRanks

34.93% upside

12 Months Forecast

Average 90.89 USD  34.93%

High 124 USD

Low 60 USD

Based on 19 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

15

Buy

4

Hold

0

Sell

Sentiment

By Acuity

1 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat